Natural killer cells in xenotransplantation

Xenotransplantation

Volumn 4, Issue 4, 1997, Pages 201-211

  Seebach, Jörg D ^a   Waneck, Gerald L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adhesion; Animal models; Endothelial cell; MHC; Natural killer cell; Porcine; Xenotransplantation

Indexed keywords

EID: 3643141189     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3089.1997.tb00184.x     Document Type: Review

References (103)

1. AUCHINCLOSS H, JR., SACHS DH. Transplantation and graft rejection. In: Paul WE, ed. Fundamental Immunology, 3rd Ed. New York: Raven Press, 1993, p. 1099.
2. LANIER LL. The role of natural killer cells in transplantation. Curr Opin Immunol 1995; 7:626.
3. BENNETT M, YU YY, STONEMAN E, REMBECKI RM, MATHEW PA, LINDAHL KF, KUMAR V. Hybrid resistance: 'Negative' and 'positive' signaling of murine natural killer cells. Semin Immunol 1995; 7:121.
4. PETERSSON E, QI ZQ, EKBERG H, ÖSTRAAT Ö, DOHLSTEN M, HEDLUND G. Activation of alloreactive natural killer cells is resistant to cyclosporine. Transplantation 1997; 63:1138.
5. PAUL LC. Chronic rejection of organ allografts: Magnitude of the problem. Transplant Proc 1993; 25:2024.
6. TRINCHIERI G. Biology of natural killer cells. Adv Immunol 1989; 47:187.
7. LANIER LL, CORLISS B, PHILLIPS JH. Arousal and inhibition of human NK cells. Immunol Rev 1997; 155:145.
8. SPITS H, LANIER LL, PHILLIPS JH. Development of human T and natural killer cells. Blood 1995; 85:2654.
9. BERKE G. The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu Rev Immunol 1994; 12:735.
10. KAGI D, LEDERMANN B, BURKI K, ZINKERNAGEL RM, HENGARTNER H. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol 1996; 14:207.
11. DENNERT G. Molecular mechanism of target lysis by cytotoxic T cells. Int Rev Immunol 1997; 14:133.
12. VUJANOVIC NL, NAGASHIMA S, HERBERMAN RB, WHITESIDE TL. Nonsecretory apoptotic killing by human NK cells. J Immunol 1996; 157:1117.
13. PHILLIPS JH, LANIER LL. Dissection of the lymphokine-activated killer phenomenon: Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986; 164:814.
14. ORTALDO JR, MASON A, OVERTON R. Lymphokine-activated killer cells: Analysis of progenitors and effectors. J Exp Med 1986; 164:1193.
15. GRIMM EA, ROBB RJ, ROTH JA, NECKERS LM, LACHMAN LB, WILSON DJ, ROSENBERG SA. Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med 1983; 158:1356.
16. PERUSSIA B, TRINCHIERI G, CEROTTINI JC. Functional studies of Fc-receptor-bearing human lymphocytes: Effect of treatment with proteolytic enzymes. J Immunol 1979; 123:681.
17. LOETSCHER P, SEITZ M, CLARK-LEWIS I, BAGGIOLINI M, MOSER B. Activation of NK cells by CC chemokines. Chemotaxis, Ca2+ mobilization, and enzyme release. J Immunol 1996; 156:322.
18. ALLAVENA P, PAGANIN C, MARTIN-PADURA I, PERI G, GABOLI M, DEJANA E, MARCHISIO PC, MANTOVANI A. Molecules and structures involved in the adhesion of natural killer cells to vascular endothelium. J Exp Med 1991; 173:439.
19. SIMON AR, WARRENS AN, SYKES M. Adhesion molecules in xenotransplantation. In: Steinhoff G, ed. Cell Adhesion Molecules in Organ Transplantation, 2nd Ed. Austin: R. G. Landes Company, 1997 (in press).
20. CARBONE E, RUGGIERO G, TERRAZZANO G, PALOMBA C, MANZO C, FONTANA S, SPITS H, KÄRRE K, ZAPPACOSTA S. A new mechanism of NK cell cytotoxicity activation: The CD40-CD40 ligand interaction. J Exp Med 1997; 185:2053.
21. CHAMBERS BJ, SALCEDO M, LJUNGGREN HG. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 1996; 5:311.
22. MULTHOFF G, BOTZLER C, JENNEN L, SCHMIDT J, ELLWART J, ISSELS R. Heat shock protein 72 on tumor cells: A recognition structure for natural killer cells. J Immunol 1997; 158:4341.
23. BEZOUSKA K, YUEN CT, O'BRIEN J, CHILDS RA, CHAI W, LAWSON AM, DRBAL K, FISEROVA A, POSPISIL M, FEIZI T. Oligosaccharide ligands for NKR-Pl protein activate NK cells and cytotoxicity. Nature 1994; 372:150.
24. DAS B, MONDRAGON MO, TAO SZ, NORIN AJ. Preferential interaction of a novel tumor surface protein (p38.5) with naive natural killer cells. J Exp Med 1997; 185:1735.
25. PATTISON JM, KRENSKY AM. New insights into mechanisms of allograft rejection. Am J Med Sci 1997; 313:257.
26. SAYEGH MH, CARPENTER CB. Role of indirect allorecognition in allograft rejection. Int Rev Immunol 1996; 13:221.
27. KÄRRE K. How to recognize a foreign submarine. Immunol Rev 1997; 155:5.
28. LJUNGGREN HG, KÄRRE K. In search of the 'missing self: MHC molecules and NK cell recognition. Immunol Today 1990; 11:237.
29. MORETTA A, BOTTINO C, VITALE M, PENDE D, BIASSONI R, MINGARI MC, MORETTA L. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996; 14:619.
30. REYBURN H, MANDELBOIM O, VALES-GOMEZ M, SHEU EG, PAZMANY L, DAVIS DM, STROMINGER JL. Human NK cells: Their ligands, receptors and functions. Immunol Rev 1997; 155:119.
31. LONG EO, BURSHTYN DN, CLARK WP, PERUZZI M, RAJAGOPALAN S, ROJO S, WAGTMANN N, WINTER CC. Killer cell inhibitory receptors: diversity, specificity, and function. Immunol Rev 1997; 155:135.
32. INVERARDI L, PARDI R. Early events in cell-mediated recognition of vascularized xenografts: Cooperative interactions between selected lymphocyte subsets and natural antibodies. Immunol Rev 1994; 141:71.
33. INVERARDI L, PARDI R. Human natural killer cells and natural antibodies recognize overlapping molecular structures on discordant xenogeneic endothelium. In: Cooper DKC, Kemp E, Platt JL, White DJG, eds. Xenotransplantation. 2nd Ed. Springer, 1997, p. 104.
34. BIRMELE B, THIBAULT G, NIVET H, GRUEL Y, BARDOS P, LEBRANCHU Y. Human lymphocyte adhesion to xenogeneic porcine endothelial cells: Modulation by human TNF-alpha and involvement of VLA-4 and LFA-1. Transplant Immunol 1996; 4:265.
35. MALYGUINE AM, SAADI S, PLATT JL, DAWSON JR. Human natural killer cells induce morphologic changes in porcine endothelial cell monolayers. Transplantation 1996; 61:161.
36. INVERARDI L, CLISSI B, STOLZER AL, BENDER JR, SANDRIN MS, PARDI R. Human natural killer lymphocytes directly recognize evolutionarily conserved oligosaccharide ligands expressed by xenogeneic tissues. Transplantation 1997; 63:1318.
37. GOODMAN DJ, MILLAN MT, FERRAN C, BACH FH. Mechanisms of delayed xenograft rejection. In: Cooper DKC, Kemp E, Paul WE, White DJG, eds. Xenotransplantation, 2nd Ed. Springer, 1997, p. 77.
38. MACH F, SCHÖNBECK U, SUKHOVA GK, BOURCIER T, BONNEFOY JY, POBER JS, LIBBY P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94:1931.
39. MAHER SE, KARMANN K, MIN W, HUGHES CCW, POBER JS, BOTHWELL ALM. Porcine endothelial CD86 is a major costimulator of xenogeneic human T cells: Cloning, sequencing, and functional expression in human endothelial cells. J Immunol 1996; 157:3838.
40. DAVIS TA, CRAIGHEAD N, WILLIAMS AJ, SCADRON A, JUNE CH, LEE KP. Primary porcine endothelial cells express membrane-bound B7-2 (CD86) and a soluble factor that co-stimulate cyclosporin A-resistant and CD28-dependent human T cell proliferation. Int Immunol 1996; 8:1099.
41. BACH FH, WINKLER H, FERRAN C, HANCOCK WW, ROBSON SC. Delayed xenograft rejection. Immunol Today 1996; 17:379.
42. GOODMAN DJ, VON ALBERTINI M, WILLISON A, MILLAN MT, BACH FH. Direct activation of porcine endothelial cells by human natural killer cells. Transplantation 1996; 61:763.
43. VON ALBERTINI MA, GOODMAN DJ, BACH FH. Direct cell contact is required to induce expression of E-selectin and IL-8 secretion in pig endothelial cells by human natural killer cells. Transplant Proc 1996; 28:608.
44. CUNNINGHAM A. Cellular aspects of xenotransplantation. Transpl Immunol 1994; 2:160.
45. KUMAGAI-BRAESCH M, SATAKE M, KORSGREN O, ANDERSSON A, MOLLER E. Characterization of cellular human anti-porcine xenoreactivity. Clin Transplant 1993; 7:273.
46. ELSEN M, SOARES M, LATINNE D, CORNET A, BAZIN H. Role of activated natural killer and CD4+, CD8+ cells in the cellular rejection of a discordant xenograft. Transplant Proc 1993; 25:447.
47. KIRK AD, LI RA, KINCH MS, ABERNETHY KA, DOYLE C, BOLLINGER RR. The human antiporcine cellular repertoire: In vitro studies of acquired and innate cellular responsiveness. Transplantation 1993; 55:924.
48. SATAKE M, KORSGREN O, RIDDERSTAD A, KARLSSON-PARRA A, WALLGREN A-C, MOLLER E. Immunological characteristics of islet cell transplantation in humans and rodents. Immunol Rev 1994; 141:191.
49. YAMADA K, SEEBACH JD, DERSIMONIAN H, SACHS DH. Human anti-pig T-cell mediated cytotoxicity. Xenotransplantation 1996; 3:179.
50. SEEBACH JD, YAMADA K, MCMORROW I, SACHS DH, DERSIMONIAN H. Xenogeneic human anti-pig cytotoxicity mediated by activated natural killer cells. Xenotransplantation 1996; 3:188.
51. SEEBACH JD, COMRACK C, GERMANA S, LEGUERN C, SACHS DH, DERSIMONIAN H. HLA-Cw3 expression on porcine endothelial cells protects against xenogeneic cytotoxicity mediated by a subset of human NK cells. J Immunol 1997 159:3655.
52. SEEBACH JD, MCMORROW IM, HOLLEY K, SACHS DH. IgG subtypes and xenogeneic antibody-dependent cell-mediated cytotoxicity mediated by Galα1,3Gal and non-Galα1,3Gal reactive natural antibodies. 4th International Congress for Xenotransplantation, Nantes, France 1997 (abstract).
53. BREVIG T, KRISTENSEN T. Direct cytotoxic response of human lymphocytes to porcine PHA-lymphoblasts and lymphocytes. APMIS 1997; 105:290.
54. CHAN DV, AUCHINCLOSS H, JR. Human anti-pig cell-mediated cytotoxicity in vitro involves non-T as well as T cell components. Xenotransplantation 1996; 3:158.
55. DONNELLY CE, YATKO C, JOHNSON EW, EDGE AS. Human natural killer cells account for non-MHC class I-restricted cytolysis of porcine cells. Cell Immunol 1997; 175:171.
56. ITESCU S, KWIATKOWSKI P, WANG SF, BLOOD T, MINANOV OP, ROSE S, MICHLER RE. Circulating human mononuclear cells exhibit augmented lysis of pig endothelium after activation with interleukin 2. Transplantation 1996; 62:1927.
57. GALILI U. Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: A major obstacle for xenotransplantation in humans. Immunol Today 1993; 14:480.
58. WATIER H, GUILLAUMIN JM, VALLEE I, THIBAULT G, GRUEL Y, LEBRANCHU Y, BARDOS P. Human NK cell-mediated direct and IgG-dependent cytotoxicity against xenogeneic porcine endothelial cells. Transplant Immunol 1996; 4:293.
59. COOKE SP, PEARSON JD, SAVAGE CO. Human IgG xenoreactive antibodies mediate damage to porcine endothelial cells in vitro by both humoral and cellular mechanisms. Transplant Immunol 1997; 5:39.
60. SCHAAPHERDER AFM, DAHA MR, TE BULTE M-TJW, VAN DER WOUDE FJ, GOOSZEN HG. Antibody-dependent cell-mediated cytotoxicity against porcine endothelium induced by a majority of human sera. Transplantation 1994; 57:1376.
61. GOODMAN DJ, VON ALBERTINI MA, MCSHEA A, WRIGHTON CJ, BACH FH. Adenoviral-mediated overexpression of IκBα in endothelial cells inhibits natural killer cell-mediated endothelial cell activation. Transplantation 1996; 62:967.
62. HUVENT I, COUSIN C, KISS A, BERNARD C, D'HALLUIN JC. Susceptibility to natural killer cells and down regulation of MHC class I expression in adenovirus 12 transformed cells are regulated by different E1A domains. Virus Res 1996; 45:123.
63. KIRK AD, HALL BL, FINN OJ, BOLLINGER RR. In vitro analysis of the human antiporcine T-cell repertoire. Transplant Proc 1992; 24:602.
64. LEVENTHAL JR, MATAS AJ, SUN LH, REIF S, BOLMAN RM, III, DALMASSO AP, PLATT JL. The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model. Transplantation 1993; 56:1.
65. BLAKELY ML, VAN DER WERF WJ, BERNDT MC, DALMASSO AP, BACH FH, HANCOCK WW. Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation 1994; 58:1059.
66. CANDINAS D, BELLIVEAU S, KOYAMADA N, MIYATAKE T, HECHENLEITNER P, MARK W, BACH FH, HANCOCK WW. T cell independence of macrophage and natural killer cell infiltration, cytokine production, and endothelial activation during delayed xenograft rejection. Transplantation 1996; 62:1920.
67. LIN Y, VANDEPUTTE M, WAER M. Natural killer cell- and macrophage-mediated rejection of concordant xenografts in the absence of T and B cell responses. J Immunol 1997; 158:5658.
68. PATSELAS T, THOMAS F, ARANEDA D, MARCHMAN W. Role of natural killer and killer cells in concordant xenograft rejection. Transplant Proc 1995; 27:262.
69. ARAKAWA K, AKAMI T, OKAMOTO M, AKIOKA K, LEE PC, SUGANO Y, KAMEI J, SUZUKI T, NAGASE H, TSUCHIHASHI Y. Prolongation of heart xenograft survival in the NK-deficient rat. Transplant Proc 1994; 26:1266.
70. THOMAS F, ARANEDA D, HENRETTA J, PITTMAN K, MARCHMAN W. Extended and expanded studies of xenograft rejection in immunodeficient animals. Transplant Proc 1994; 26:1224.
71. RAPPOCCIOLO G, ALLAN JS, EICHBERG JW, CHANH TC. A comparative study of natural killer cell activity, lymphoproliferation, and cell phenotypes in nonhuman primates. Vet Pathol 1992; 29:53.
72. MALYGUINE AM, SAADI S, PLATT JL, DAWSON JR. Differential expression of natural killer cell markers: human versus baboon. Transplantation 1996; 62:1319.
73. KIRK AD, HEINLE JS, MAULT JR, SANFILIPPO F. Ex vivo characterization of human anti-porcine hyperacute cardiac rejection. Transplantation 1993; 56:785.
74. IBRAHIM S, KIRK AD, SANFILIPPO F. Phenotype of infiltrating cells in an ex vivo model of human antiporcine hyperacute cardiac xenograft rejection. Transplant Proc 1996; 28:777.
75. COLLINS BH, CHARI RS, MAGEE JC, HARLAND RC, LINDMAN BJ, LOGAN JS, BOLLINGER RR, MEYERS WC, PLATT JL. Mechanisms of injury in porcine livers perfused with blood of patients with fulminant hepatic failure. Transplantation 1994; 58:1162.
76. INVERARDI L, SAMAJA M, MOTTERLINI R, MANGILI F, BENDER JR, PARDI R. Early recognition of a discordant xenogeneic organ by human circulating lymphocytes. J Immunol 1992; 149:1416.
77. KAPLON RJ, MICHLER RE, XU H, KWIATKOWSKI PA, EDWARDS NM, PLATT JL. Absence of hyperacute rejection in newborn pig-to-baboon cardiac xenografts. Transplantation 1995; 59:1.
78. SABLINSKI T, GIANELLO PR, BAILIN M, BERGEN KS, EMERY DW, FISHMAN JA, FOLEY A, HATCH T, HAWLEY RJ, KOZLOWSKI T, LORF T, MEEHAN S, MONROY R, POWELSON JA, COLVIN RB, COSIMI AB, SACHS DH. Pig to monkey bone marrow and kidney xenotransplantation. Surgery 1997; 121:381.
79. GENGOZIAN N, GOOD RA, FU SM. Development and characterization of monoclonal antibodies to lymphocyte cell surface antigens of the rhesus monkey. Transplantation 1992; 53:1306.
80. PRUITT SK, BOLLINGER RR, COLLINS BH, MARSH HC, JR., LEVIN JL, RUDOLPH AR, BALDWIN WM, III, SANFILIPPO F. Effect of continuous complement inhibition using soluble complement receptor type 1 on survival of pig-to-primate cardiac xenografts. Transplantation 1997; 63:900.
81. KORSGREN O. Acute cellular xenograft rejection. Xenotransplantation 1997; 4:11.
82. MANDEL TE, KOVARIK J, KOULMANDA M, GEORGIOU HM. Cellular rejection of fetal pancreas grafts: Differences between allo- and xenograft rejection. Xenotransplantation 1997; 4:2.
83. KARLSSON-PARRA A, RIDDERSTAD A, WALLGREN AC, MOLLER E, LJUNGGREN HG, KORSOREN O. Xenograft rejection of porcine islet-like cell clusters in normal and natural killer cell-depleted mice. Transplantation 1996; 61:1313.
84. BENDA B, KARLSSON-PARRA A, RIDDERSTAD A, KORSGREN O. Xenograft rejection of porcine islet-like cell clusters in immunoglobulin- or Fc-receptor gamma-deficient mice. Transplantation 1996; 62:1207.
85. SHARABI Y, AKSENTIJEVICH I, SUNDT III TM, SACHS DH, SYKES M. Specific tolerance induction across a xenogeneic barrier: Production of mixed rat/mouse lymphohematopoietic chimeras using a nonlethal preparative regimen. J Exp Med 1990; 172:195.
86. LEE LA, SERGIO JJ, SYKES M. Natural killer cells weakly resist engraftment of allogeneic, long-term, multilineage-repopulating hematopoietic stem cells. Transplantation 1996; 61:125.
87. MARCUS H, FACTOROVICH Y, KULOVA L, DENES L, SEGAL H, DAVID M, BURAKOVA T, REISNER Y. Allograft and xenograft rejection in C3H/SCID mice. A new model for the study of non-T cell graft rejection mechanisms. Transplantation 1996; 61:777.
88. SMYTH MJ, KERSHAW MH, TRAPANI JA. Xenospecific cytotoxic T lymphocytes: Potent lysis in vitro and in vivo. Transplantation 1997; 63:1171.
89. KOS FJ, ENGLEMAN EG. Requirement for natural killer cells in the induction of cytotoxic T cells. J Immunol 1995; 155:578.
90. SAWADA T, DELLAPELLE PA, SEEBACH JD, SACHS DH, COLVIN RB, IACOMINI J. Human cell-mediated rejection of porcine xenografts in an immunodeficient mouse model. Transplantation 1997; 63:1331.
91. MOSS A, JR., FRYER JP, LEVENTHAL JR, SIMONE P, CHEN S, REINSMOEN N, MATAS AJ. Analysis of the human anti-pig cellular immune response using the Hu-scid mouse-porcine skin graft model. Transplant Proc 1994; 26:1209.
92. SHIROKI R, NAZIRUDDIN B, SHISHIDO S, DUFFY BF, HOWARD T, MOHANAKUMAR T. Human peripheral blood leukocyte-reconstituted severe combined immunodeficient mouse: Analysis of the human immune response against porcine islet transplantation. Transplantation 1997; 63:818.
93. ARTRIP JH, KWIATKOWSKI PA, WANG S-F, MINANOV OP, MORGENTHAU A, MICHLER RE. Lysis of porcine endothelium by IL-2 activated primate mononuclear cells involves interactions with galactose a1,3-galactose. J Heart Lung Transplant 1997; 16: 58 (abstract).
94. TORGERSEN KM, SALCEDO M, VAAGE JT, NAPER C, ROLSTAD B, LJUNGGREN HG, HÖGLUND P. Major histocompatibility complex class I-independent killing of xenogenic targets by rat allospecific natural killer cells. Transplantation 1997; 63:119.
95. SEEBACH JD, HOLLEY K, LI Z, COMRACK C, GERMANA S, LEGUERN A, PAGUIO CG, VICART P, PAULIN D, LEGUERN C, SACHS DH. Transformed pig bone-marrow derived endothelial cells: A useful tool to study both cellular and humoral xenogeneic immunity in vitro. 4th International Congress for Xenotransplantation, Nantes, France 1997 (abstract).
96. CLAYBERGER C, KRENSKY AM. Immunosuppressive peptides corresponding to MHC class I sequences. Curr Opin Immunol 1995; 7:644.
97. WALKER PR, SAAS P, DIETRICH PY. Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back. J Immunol 1997; 158:4521.
98. CUTURI MC, JOSIEN R, DOUILLARD P, PANNETIER C, CANTAROVICH D, SMIT H, MENORET S, POULETTY P, CLAYBERGER C, SOULILLOU JP. Prolongation of allogeneic heart graft survival in rats by administration of a peptide (aa 75-84) from the alpha 1 helix of the first domain of HLA-B7 01. Transplantation 1995; 59:661.
99. EISCHEN CM, SCHILLING JD, LYNCH DH, KRAMMER PH, LEIBSON PJ. Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol 1996; 156:2693.
100. LAU HT, YU M, FONTANA A, STOECKERT CJ, JR. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273:109.
101. BELLGRAU D, GOLD D, SELAWRY H, MOORE J, FRANZUSOFF A, DUKE RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377:630.
102. ALLISON J, GEORGIOU HM, STRASSER A, VAUX DL. Transgenic expression of CD95 ligand on islet b cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94:3943.
103. KANG SM, SCHNEIDER DB, LIN ZH, HANAHAN D, DICHEK DA, STOCK PG, BAEKKESKOV S. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med 1997; 3:738.